Trevena Inc. (NASDAQ:TRVN) rose 2.4% during mid-day trading on Monday . The company traded as high as $7.46 and last traded at $7.37, with a volume of 151,852 shares changing hands. The stock had previously closed at $7.20.

TRVN has been the subject of a number of research reports. Cowen and Company reiterated a “buy” rating on shares of Trevena in a research report on Tuesday, May 3rd. Brean Capital reiterated a “buy” rating on shares of Trevena in a research report on Tuesday, May 3rd. Needham & Company LLC reiterated a “buy” rating on shares of Trevena in a research report on Tuesday, May 3rd. FBR & Co reiterated a “buy” rating and set a $16.00 price target on shares of Trevena in a research report on Wednesday, May 4th. Finally, Wedbush reiterated an “outperform” rating and set a $20.00 price target on shares of Trevena in a research report on Thursday, May 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. Trevena has a consensus rating of “Buy” and a consensus price target of $14.30.

The company has a 50 day moving average of $6.77 and a 200-day moving average of $7.48. The stock’s market capitalization is $387.16 million.

Trevena (NASDAQ:TRVN) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.01. Equities analysts anticipate that Trevena Inc. will post ($1.55) earnings per share for the current fiscal year.

In related news, CEO Maxine Gowen purchased 22,084 shares of Trevena stock in a transaction dated Friday, May 27th. The stock was bought at an average cost of $7.12 per share, with a total value of $157,238.08. Following the purchase, the chief executive officer now owns 279,025 shares in the company, valued at approximately $1,986,658. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Other hedge funds recently modified their holdings of the company. Jennison Associates LLC raised its stake in shares of Trevena by 0.3% in the fourth quarter. Jennison Associates LLC now owns 702,341 shares of the biopharmaceutical company’s stock worth $7,375,000 after buying an additional 2,341 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Trevena by 15.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 216,705 shares of the biopharmaceutical company’s stock worth $2,275,000 after buying an additional 29,300 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Trevena during the fourth quarter worth $1,929,000.

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.